AaronPatrickTansyMD

Neurology • South Plainfield, NJ

Neuroimaging, Vascular Neurology, Neurodegenerative

Sr. Medical Director, Clinical Development PTC Therapeutics, Inc.

Join to view full profile

Dr. Tansy is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Tansy's full profile

Already have an account?

Office
100 Corporate Court
South Plainfield, NJ 07080

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Vascular Neurology, 2012 - 2013
New York Presbyterian Hospital (Columbia Campus)Residency, Neurology, 2006 - 2009
New York Presbyterian Hospital (Columbia Campus)Residency, Neurology, 2005 - 2008
The MetroHealth System/Case Western Reserve UniversityInternship, Internal Medicine, 2005 - 2006
Case Western Reserve University School of MedicineClass of 2005

Certifications & Licensure

NY State Medical License 2006 - 2026
American Board of Psychiatry and Neurology Neurology
American Board of Psychiatry and Neurology Vascular Neurology

Clinical Trials

Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS Start of enrollment: 2022 May 15
Active, not recruiting
Phase 2
A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria Start of enrollment: 2022 Feb 14
Recruiting
Phase 3
A Study of PTC923 in Participants With Phenylketonuria Start of enrollment: 2021 Sep 30
Completed
Phase 3
A Study of OV101 in Individuals With Angelman Syndrome (AS) Start of enrollment: 2019 Sep 09
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

1 citations
First-in-Human Studies of Pharmacokinetics and Safety of Utreloxastat (PTC857), a Novel 15-Lipooxygenase Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis.
Lan Gao, Peter Giannousis, Martin Thoolen, Diksha Kaushik, Joey Latham
Clinical Pharmacology in Drug Development. 2023-02-01
27 citations
A randomized, placebo-controlled phase 2 trial of laquinimod in primary progressive multiple sclerosis
Gavin Giovannoni, Volker Knappertz, Joshua R. Steinerman, Aaron P. Tansy, Thomas Li
Neurology. 2020-08-25
12 citations
Defining responders to therapies by a statistical modeling approach applied to randomized clinical trial data
Francesca Bovis, Luca Carmisciano, Alessio Signori, Matteo Pardini, Joshua R. Steinerman
BMC Medicine. 2019-06-18

Professional Memberships

American Academy of Neurology - AAN
Member

External Links

PTC Therapeutics http://www.ptcbio.com